Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 6, 2008, Pages 601-608

  Cunnington, Marianne ^a   Webb, David ^a   Qizilbash, Nawab ^b,e   Blum, David ^c   Mander, Adrian ^a   Jonsson Funk, Michele ^d   Weil, John ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b OXON Epidemiology Ltd   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d IL   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular risk; Cox 2 inhibitor; NSAIDS; Osteoarthritis; Retrospective cohort

Indexed keywords

ANION EXCHANGE RESIN; ANTIHYPERTENSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPROXEN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB; ISOXAZOLE DERIVATIVE; LACTONE; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE;

ACUTE HEART INFARCTION; ADULT; AGED; AGING; ANAMNESIS; ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHRONIC BRONCHITIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SMOKING; TREATMENT DURATION; AGE; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; FOLLOW UP; HEART INFARCTION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STROKE; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPROXEN; OSTEOARTHRITIS; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SULFONAMIDES; SULFONES; UNITED STATES;

EID: 46349108812     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1590     Document Type: Article

References (19)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
2. Solomon DH, Schneeweiss S, Glynn R, et al. Relationship between selective cyclooxygenase 2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-2073.
3. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. Cox 2 selective non-steroidal anti-inflammaotry drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
4. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase 2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 360:1751-1756.
5. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481.
6. Bresalier RS, Sandler RS, Quan H, et al. Adenomatous Polyp Provention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
7. Lagakos SW. Time-to-event analyses for long-term treatments - the APPROVe Trial. N Engl J Med 2006, 355: 113-117.
8. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157-164.
9. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the eldedy. Arch Intern Med 2003; 163: 481-486.
10. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481-489.
11. Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf 2006; 15: 641-652.
12. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005; 330: 1366.
13. Feudjo-Tepie M, Kiri V, Qizilbash N, Boudiaf N, Evans SJW. Waiting Time Bias In Drug Safety And Effectiveness Cohort Analyses Using Clinical Practice Databases. ISPE, Philadelphia, August 2003.
14. StataCorp. 2003; Stata Statistical Software: Release 8. StataCorp LP: College Station, TX.
15. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
16. Watson JW, Rhodes T, Cai B, Guess HA. Lower risks of thrombolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105-1110.
17. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-263.
18. Smalley WE, Ray WA, Daugherty J, Griffin MR. Nonsteroidal anti-inflammatory drug use and colorectal cancer incidence: a population-based study. Arch Intern Med 1999; 159: 161-166.
19. Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-496.